Skip to content
Accessibility help
Search NICE…
Skip to content
Menu
Sign in
Guidance
Standards and indicators
Life sciences
British National Formulary (BNF)
British National Formulary for Children (BNFC)
Clinical Knowledge Summaries (CKS)
About
Home
NICE guidance
In development
Guidance, NICE advice and quality standards
In development
Skip to filters
Skip to results
Published
In consultation
In development
Awaiting development
Topic selection
Filter (1 active)
Skip to results
Filter by title or keyword
Filter
Expected publication date
Expected publication date
From date
To date
Apply date filters
Area of interest
Area of interest
COVID-19 (7)
Type
(
1 selected
)
Type
Guidance (373)
NICE advice (1)
Quality standard (9)
Guidance programme
Guidance programme
Clinical guidelines (27)
Diagnostics guidance (9)
Health technology evaluations (11)
Highly specialised technologies guidance (8)
Interventional procedures guidance (10)
Medical technologies guidance (11)
NICE guidelines (30)
Public health guidelines (1)
Technology appraisal guidance (302)
Apply filters
Showing 291 to 300 of 373
Sort by
Title
Date
Apply sorting
Type: Guidance
Remove Type: Guidance filter
Guidance, NICE advice and quality standards in development
Title
Type
Expected publication date
Rozanolixizumab for treating antibody-positive generalised myasthenia gravis [ID5092]
Technology appraisal guidance
TBC
Rucaparib for maintenance treatment of advanced ovarian, fallopian tube and peritoneal cancer after response to first-line platinum-based chemotherapy [ID5100]
Technology appraisal guidance
21 August 2024
Rucaparib for maintenance treatment of relapsed platinum-sensitive ovarian, fallopian tube or peritoneal cancer (Review of TA611) [ID4069]
Technology appraisal guidance
12 June 2024
Ruxolitinib for treating acute graft versus host disease refractory to corticosteroids in people aged 12 and over [ID6377]
Technology appraisal guidance
TBC
Ruxolitinib for treating moderate to severe chronic graft-versus-host disease after an allogeneic stem cell transplant in people 28 days to 17 years [ID6427]
Technology appraisal guidance
TBC
Ruxolitinib for treating non-segmental vitiligo in people 12 years and over [ID3998]
Technology appraisal guidance
31 July 2024
Sacituzumab govitecan for treating advanced non-small-cell lung cancer after platinum-based chemotherapy and a PD-1 or PD-L1 inhibitor [ID6375]
Technology appraisal guidance
TBC
Sacituzumab govitecan for treating hormone receptor-positive HER2-negative metastatic breast cancer after 2 or more therapies [ID4033]
Technology appraisal guidance
TBC
Sacral nerve stimulation for idiopathic chronic non-obstructive urinary retention
Interventional procedures guidance
TBC
Secukinumab for treating enthesitis-related arthritis or juvenile psoriatic arthritis [ID3738]
Technology appraisal guidance
TBC
Previous page
1
…
28
29
Current page
30
31
32
…
38
Page
30
of
38
Next page
Results per page
10
25
50
All
Back to top